Wednesday, February 05, 2020 5:50:06 PM
As we all know this is a very recent development and, therefore, there is not much information to go about.
I came across a very interesting paper published by Delhi's Kusuma School of biological sciences, IIT. They used computational tools to analyze the sequence and structural features of 2019-nCoV
https://www.biorxiv.org/content/10.1101/2020.01.30.927871v1.full.pdf
Their conclusions are very interesting, below a summary that concerns us (emphasis are mine):
1) The amino acid sequence presents 4 insertions (an insertion is a modification in the “normal” amino genomic sequence) of that are not present in other coronaviruses analyzed
2) Surprisingly, each of the four inserts aligned with short segments of the Human immunodeficiency Virus-1 (HIV-1) proteins
3) The first 3 inserts aligned to short segments of amino acid residues in HIV-1 gp120 (glycoprotein GP120 is a glycoprotein exposed on the surface of the HIV envelope), the insert 4 aligned to HIV-1 Gag (with gaps). Gag , or group specific antigen, is the major structural protein of HIV-1 and all other retroviruses and comprises about 50% of the mass of a viral particle.
4) It is unlikely that all 4 inserts in the 2019-nCoV spike glycoprotein fortuitously match with 2 key structural proteins of an unrelated virus (HIV-1).
5) The novel inserts are part of the receptor binding site of 2019-nCoV
And they mention that:
So, it could be argued that a CCR5 antagonist, could very well play a role in controlling the virus due to its capacity to bind to gp120.
Of course, all of the above out of one paper only. The Chinese know better by now with their practical experience and it will be very interesting to hear what Dr. Patterson has to say tomorrow.
I greatly enjoyed, and learnt, from your article about GILD (and CYDY) in SA. Congratulations !!!, very well written and researched
I hope it can bring them to their senses before few Billion dollars if their revenue disappear ...
Recent CYDY News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/09/2024 02:30:20 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/01/2024 10:16:47 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/01/2024 10:15:34 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 02/22/2024 10:16:11 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/22/2024 05:15:08 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 02/16/2024 02:00:24 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/12/2024 10:31:57 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/29/2024 10:22:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/29/2024 01:40:14 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/19/2024 10:15:35 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/16/2024 10:16:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2024 02:04:57 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2024 02:04:20 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2024 02:02:59 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2024 02:02:30 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2024 02:01:55 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2024 02:01:14 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/22/2023 10:15:19 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM